Viridian Therapeutics Posts $24.7 Million in Q3 Product Revenue, $101.2 Million Net Loss
Viridian Therapeutics reported Q3 2026 net product revenue of $24.7M and a net loss of $101.2M. Total revenue was $25.8M, with $955.2M in cash reserves. Lumvoa had over 100 patients on therapy. The company plans to submit a BLA for elegrobart in Q1 2027 and start a phase 1 trial for VRDN-292 in Q4 2026.
How this was made

The 30-second read
Why it matters
The earnings report reveals a substantial net loss despite a healthy cash runway, likely prompting short‑term downside while long‑term catalysts remain in the pipeline.
Market read
Primary earnings disclosure for a micro‑cap biotech; new financials and pipeline updates provide fresh trading data.
What to watch
CMS J‑code assignment and upcoming BLA filing for elegrobart may unlock future revenue.
Background
Viridian Therapeutics (VRDN) released its Q3 2026 earnings, highlighting product revenue, cash position, and pipeline milestones.
Ticker impact
Q3 2026 earnings disclosed net product revenue $24.7M, net loss $101.2M, cash $955.2M and pipeline updates.
downward pressure as investors price the large net loss
The loss magnitude and modest revenue are worse than typical for a cash‑rich biotech, suggesting short‑term sell pressure.
Market effects
Biotech peers may face similar valuation pressure after a loss‑heavy earnings season.
US market, primarily Nasdaq biotech segment.
Limited to investors tracking US‑listed biotech stocks.
Counterpoint
Strong cash balance and pipeline progress could support a rebound if upcoming trials succeed.
Key entities
- companyViridian Therapeutics
US‑listed biotech reporting Q3 results.
